Drug Database
Back to search

Poland· PL-100453730

Brastib

A lapatinib product containing lapatinibum, registered in Poland by STADA Arzneimittel AG. The same ATC class is registered in 12 of our 19 countries.

ATC L01EH01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedBrastibATCL01EH01REGISTER NO.PL-100453730PACKS LISTED3CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lapatinibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lapatinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EH01 (lapatinib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search lapatinib products by name

Lapatinib · ATC L01EH01

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lapatinib costs, country by country.

Normalised to the WHO defined daily dose (1.25 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Lapatinib · price per daily dose (1.25 g)

USD · FX 28 Sept 2026

  • CH Switzerland$101.12
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Lapatinibum
Manufacturer
STADA Arzneimittel AG
Country
Poland (PL)
ATC code
L01EH01
ATC class
Lapatinib
Defined daily dose
1.25 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991507817
  • gtin
    05909991507824
  • gtin
    05909991507831

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

675 interactions on record for lapatinib.

Graded by severity as the source publishes them — 124 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lapatinib against other medicinesHow interaction checks work

Lapatinib · interactions on record

675 records

  • 124 severe
  • 537 moderate
  • 14 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • LoperamideA07DA03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lapatinib in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lapatinib products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Cyprus · Laprem
  • Germany · Lapatinib Al, Lapatinib Stada
  • Denmark · Lapatinib Newbury
  • Spain · Lapatinib Stada
  • France · Lapatinib Pharos
  • Iceland · Lapatinib Newbury, Tyverb
  • Liechtenstein · Tyverb
  • Malta · Lapatinib Pharos
  • Netherlands · Brastib, Lapatinib Pharos
  • Norway · Tyverb
  • Romania · Lapatinib Stada
  • Sweden · Lapatinib Newbury
  • Slovakia · Lapatinib Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8f8b8c9a-46f0-4199-a512-f25a0507320d
GET /v1/drugs/8f8b8c9a-46f0-4199-a512-f25a0507320d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "250 mg",
  "packaging": "05909991507817 ¦ Rpz ¦ 148934\n70 tabl.\n05909991507824 ¦ Rpz ¦ 148935\n84 tabl.\n05909991507831 ¦ Rpz ¦ 148936\n140 tabl.",
  "substance": "Lapatinibi ditosilas monohydricus 405 mg",
  "common_name": "Lapatinibum",
  "pl_product_id": "100453730",
  "pozwolenie_nr": "27642",
  "auth_procedure": "DCP",
  "authorisation_validity": "2028-02-02"
}
API referenceMCP serverPlans

See everything about lapatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console